Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation TCT 2022

TCT 389: First Report of Percutaneous Left Atrial Appendage Occlusion with Watchman FLX with TEE Guidance and Zero-contrast

Presenter: Tarun Chakravarty

September 19, 2022

Presentation TCT 2022

TCT 387: Saftey of Protamine Adminstration After Percutaneous Left Atrial Appendage Occlusion

Presenter: Ahmed El Shaer

September 18, 2022

Presentation TCT 2022

TCT 386: A Comparative Meta-Analysis of Newer Percutaneous Left Atrial Appendage Occlusion Devices

Presenter: Gauravpal Singh Gill

September 18, 2022

Presentation TCT 2022

TCT 385: Outcomes of Same day Compared to Next day Discharge for Patients Undergoing Left Atrial Appendage Occlusion

Presenter: Riaz Mahmood

September 18, 2022

Presentation TCT 2022

TCT 384: Real-World Practices in the Use of and Adherence to Antithrombotic and Antiplatelet Therapies Before and After Left Atrial Appendage Closure

Presenter: Jennifer Rymer

September 18, 2022

Presentation TCT 2022

TCT 383: Effect of Adding a Novel Coating to the Next-Generation Watchman Device in a Challenging Experimental Animal Model

Presenter: Walid Saliba

September 18, 2022

Presentation TCT 2022

TCT 382: Cardiac Computed Tomographic Assessment of Residual Left Atrial Appendage Patency Following Left Atrial Appendage Closure

Presenter: Sung-Han Yoon

September 18, 2022

Presentation TCT 2022

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Presenter: Davide Cao

September 18, 2022

Presentation TCT 2022

TCT 380: Predicting Device Related Thrombosis Using Computational Fluid Dynamics

Presenter: Brennan Vogl

September 18, 2022

Presentation TVT 2019

Simultaneous LAA Closure With Structural Heart Procedures - WATCHMAN IN TAVR PATIENT

Presenter: Praveen Chandra

June 14, 2019

Presentation LAA 2017

The PFO Clinic: Patient Identification, Risk/Benefit Discussions, Post-PFO Closure Medications, and Follow-Up

Presenter: Mark Reisman

July 22, 2017

Presentation LAA 2017

Watchman: Complication Frequency, Prevention, Recognition, and Management

Presenter: Jacqueline Saw

July 21, 2017

Presentation JIM 2017

Clinical Experience With LAmbre LAA CLOSURE System

Presenter: Horst Sievert

February 09, 2017

Presentation TVT 2016

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Presenter: Fabian Nietlispach

June 17, 2016

Presentation ECHO 2016

Clinical Decision Making: Stroke and Structural Interventions

Presenter: Robert J. Sommer

March 23, 2016

Presentation Scripps 2016

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

Presenter: Brian Whisenant

February 04, 2016

Presentation

Iberian Registry: 2-Year Clinical Outcomes After LAA Closure With the Amplatzer Device

Presenter: Ram?n L?pez M?nguez

January 14, 2015

Presentation

Percutaneous LAA Closure vs Warfarin for A-fib:A Randomized Clinical Trial

Presenter: Vivek Y. Reddy

November 19, 2014

Presentation TCT 2014

Left Atrial Appendage Occlusion: Which Patient and Which Device?

Presenter: Philippe Généreux, Nicolo Piazza, Samer Mansour, Jean-Michel Paradis, David A. Wood

September 13, 2014

Presentation TCT 2014

Clinical Data and Rationale for Left Atrial Appendage Closure

Presenter: Gabriel Maluenda

September 13, 2014

Advertisement

TCT 389: First Report of Percutaneous Left Atrial Appendage Occlusion with Watchman FLX with TEE Guidance and Zero-contrast

TCT 387: Saftey of Protamine Adminstration After Percutaneous Left Atrial Appendage Occlusion

TCT 386: A Comparative Meta-Analysis of Newer Percutaneous Left Atrial Appendage Occlusion Devices

TCT 385: Outcomes of Same day Compared to Next day Discharge for Patients Undergoing Left Atrial Appendage Occlusion

TCT 384: Real-World Practices in the Use of and Adherence to Antithrombotic and Antiplatelet Therapies Before and After Left Atrial Appendage Closure

TCT 383: Effect of Adding a Novel Coating to the Next-Generation Watchman Device in a Challenging Experimental Animal Model

TCT 382: Cardiac Computed Tomographic Assessment of Residual Left Atrial Appendage Patency Following Left Atrial Appendage Closure

TCT 381: Vitamin K Antagonists, Direct Oral Anticoagulants, or Left Atrial Appendage Closure for Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

TCT 380: Predicting Device Related Thrombosis Using Computational Fluid Dynamics

Simultaneous LAA Closure With Structural Heart Procedures - WATCHMAN IN TAVR PATIENT

The PFO Clinic: Patient Identification, Risk/Benefit Discussions, Post-PFO Closure Medications, and Follow-Up

Watchman: Complication Frequency, Prevention, Recognition, and Management

Clinical Experience With LAmbre LAA CLOSURE System

Combined TAVR and Left Atrial Appendage Closure in AS Patients With Atrial Fibrillation: Case Selection, Procedural Consideration, and Clinical Outcomes

Clinical Decision Making: Stroke and Structural Interventions

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

Iberian Registry: 2-Year Clinical Outcomes After LAA Closure With the Amplatzer Device

Percutaneous LAA Closure vs Warfarin for A-fib:A Randomized Clinical Trial

Left Atrial Appendage Occlusion: Which Patient and Which Device?

Clinical Data and Rationale for Left Atrial Appendage Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content